Haw v. Idaho State Board of Medicine

90 P.3d 902, 140 Idaho 152, 2004 Ida. LEXIS 63
CourtIdaho Supreme Court
DecidedApril 22, 2004
Docket29566
StatusPublished
Cited by10 cases

This text of 90 P.3d 902 (Haw v. Idaho State Board of Medicine) is published on Counsel Stack Legal Research, covering Idaho Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Haw v. Idaho State Board of Medicine, 90 P.3d 902, 140 Idaho 152, 2004 Ida. LEXIS 63 (Idaho 2004).

Opinion

EISMANN, Justice.

This is an appeal of an order from the Board of Medicine that permanently restricted the physician’s license, imposed fines totaling $20,000, and assessed costs and attorney fees totaling $116,067.05. We affirm the license restriction, reverse the fines, vacate the attorney fees and costs, and remand for further proceedings.

*155 I. FACTS AND PROCEDURAL HISTORY

In August 1993, the Idaho State Board of Medicine (Board) began receiving complaints relating to the refusal of the defendant-appellant Terek Haw, M.D., to provide patient records to physicians who later treated his patients. Ultimately, the Board had an investigator select from Dr. Haw’s medical records twenty-one patient files. Eight of them involved complaints that had been made to the Board and the remaining thirteen were selected at random. Those twenty-one files were then sent for review to a number of physicians selected by the Board.

On October 5, 2000, the Board filed a twenty-one-eount complaint against Dr. Haw alleging that the medical care he had provided to the twenty-one patients fell below the applicable standard of health care. On December 15, 2000, the Board filed an amended complaint adding two more counts, both of which involved care provided to some of the patients already named in the original complaint. The matter was tried before a hearing officer beginning on January 8, 2001, and continuing thereafter until February 26, 2001. On October 26, 2001, the hearing officer issued his proposed findings of fact and conclusions of law and proposed order.

After reviewing the record, the Board on January 23, 2002, issued its findings of fact, conclusions of law, and final order. It adopted the hearing officer’s recommended findings of fact and conclusions of law, and it made additional findings of fact and conclusions of law.

Although the complaint alleged multiple violations of the standard of care with respect to each patient, the major issue was Dr. Haw’s practice of using estrogen injections in hormone replacement therapy. Hormone replacement therapy is the use of prescribed hormones by a physician to treat a low or absent level of hormones in an individual. The cause of hormone deficiencies in women is generally related to ovarian failure at, or in some instances prior to, menopause or to the surgical removal of the ovaries. In such cases, hormone replacement therapy is used to treat the symptoms of estrogen deficiency and to maintain bone integrity and prevent osteoporosis. It may also have a secondary effect of reducing the woman’s total cholesterol and LDL cholesterol. The risks of hormone replacement therapy include a potential for blood clots, an increased risk of gallstones, an increased risk of endometrial cancer in women who have a uterus and receive unopposed estrogen, a risk of the growth of estrogen-dependent tumors, and a risk of endometriosis. Some of these risks are dose related, meaning the higher the dose the greater the risk.

Estrogen can be delivered in pill form, by transdermal patches, and through injections. Each has its benefits and detriments. Pills are easy to take, but estrogen received in this form is initially processed by the liver and may not be assimilated or tolerated well by all women. Transdermal patches deliver estrogen in more consistent doses and in a manner that initially bypasses the liver, but the patches irritate the skin of some women. Estrogen delivered by injections also bypasses the liver and may be more effective in some patients. It can create, however, dependence and addictive behavior. With injections, the levels of estrogen peak at a very high level a week or two after the injection, and then they fall. Higher and higher doses are often required because the patient starts withdrawing from the hormones sooner and sooner. The woman may then start seeking recurrent injections at higher and higher doses over time and become desperate to obtain the next injection.

Idaho Code § 54-1814(7) provides that a licensed physician is subject to discipline by the Board if the physician provides health care “which fails to meet the standard of health care provided by other qualified physicians in the same community or similar communities, taking into account his training, experience and the degree of expertise to which he holds himself out to the public.” The Board found that the standard of health care in Boise, Idaho, in the practice of hormone replacement therapy is: (a) to first utilize pills or patches, and not to use estrogen injections as an initial treatment; (b) to use the lowest estrogen dose necessary to treat the symptoms associated with estrogen deficiency; (c) to use estrogen injections if *156 the patient does not respond or has a negative reaction to estrogen replacement by the pill or patch; (d) when estrogen injections are used, to inject 10-20 milligrams every four weeks for estradiol valerate, the type used by Dr. Haw; and (e) to use an FSH blood test before commencing hormone replacement therapy to help determine ovarian function if it is not clear whether a patient is menopausal.

The manufacturer’s package insert for estradiol valerate states that the Food and Drug Administration has approved its short-term use for the treatment of moderate to severe vasomotor symptoms, atrophic vaginitis, kraurosis vulvae associated with menopause, and cyclical use only for the treatment of female hypogonadism, female castration or primary ovarian failure. The insert further provides that the dosage for these indications is 10-20 milligrams every four weeks, that the lowest dose that will control symptoms should be chosen, and that the medication should be discontinued as promptly as possible. The insert recommends that attempts to discontinue or taper medication should be made at three to six month intervals. The FDA had approved use of a single 10-25 milligram injection to prevent postpartum breast engorgement and injections every one or two weeks of 30 or more milligrams for palliative treatment of inoperable, progressing prostatic carcinoma. The manufacture of estradiol valerate was discontinued in 1999, and it was replaced with a drug having the brand name of Depo-Estradiol. The package inserts for it contained essentially the same recommendations as estradiol valerate.

The Board found by clear and convincing evidence that, in administering hormone injections to eighteen patients treated at various times during the period from April 1985 to the date of the hearing, Dr. Haw administered estrogen injections in higher dosages and at greater frequencies than permitted by the standard of health care in Boise, Idaho. The dosages that Dr. Haw administered to these patients ranged from 15 milligrams every three weeks to 50 milligrams every two weeks. In fourteen of the cases, Dr. Haw increased the dosage during the course of treatment, and the length of treatment ranged from two and one-half months to over fourteen years. With respect to two of those patients, the Board also found that he violated the standard of care by failing to utilize the FSH blood test in diagnosing or assessing their estrogen levels. It also found that he had violated the standard of care by initiating and continuing to use estrogen injections with one of those patients and by using unopposed estrogen even though she had a uterus. The Board found that Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

State v. Crist
Idaho Supreme Court, 2025
Walsh v. Swapp Law
Idaho Supreme Court, 2020
Pines, D.O. v. State Board of Medicine
351 P.3d 1203 (Idaho Supreme Court, 2015)
Armando Keto Arambula v. State
Idaho Court of Appeals, 2012
Karel v. State
162 P.3d 758 (Idaho Supreme Court, 2007)
Haw v. Idaho State Board of Medicine
137 P.3d 438 (Idaho Supreme Court, 2006)
Sons & Daughters of Idaho, Inc. v. Idaho Lottery Commission
132 P.3d 416 (Idaho Supreme Court, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
90 P.3d 902, 140 Idaho 152, 2004 Ida. LEXIS 63, Counsel Stack Legal Research, https://law.counselstack.com/opinion/haw-v-idaho-state-board-of-medicine-idaho-2004.